ストックスクリーナーアプリを入手
11.06
2.38%
-0.27
アフターアワーズ：
10.83
-0.23
-2.08%
前日終値:
$11.33
開ける：
$11.47
24時間の取引高:
691.20K
Relative Volume:
0.65
時価総額：
$1.79B
収益：
-
当期純損益:
$-274.18M
株価収益率:
-6.437
EPS:
-1.7182
ネットキャッシュフロー:
$-198.33M
1週間 パフォーマンス:
-0.54%
1か月 パフォーマンス:
+11.27%
6か月 パフォーマンス:
+12.51%
1年 パフォーマンス:
-35.13%
1日の値動き範囲:
$10.87
$11.51
1週間の範囲:
$10.43
$11.57
52週間の値動き範囲:
$8.33
$21.00
Neumora Therapeutics Inc Stock (NMRA) Company Profile
名前
Neumora Therapeutics Inc
セクター
電話
(857) 760-0900
住所
490 ARSENAL WAY, SUITE 200, WATERTOWN
NMRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
11.06 | 1.79B | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.35 | 102.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 77.21B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.96 | 37.07B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.01 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.58 | 26.99B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-05 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-22 | 開始されました | Needham | Buy |
| 2024-07-08 | 開始されました | Mizuho | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Hold |
| 2023-10-10 | 開始されました | BofA Securities | Buy |
| 2023-10-10 | 開始されました | Guggenheim | Buy |
| 2023-10-10 | 開始されました | JP Morgan | Overweight |
| 2023-10-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-10-10 | 開始されました | Stifel | Buy |
| 2023-10-10 | 開始されました | William Blair | Outperform |
すべてを表示
Neumora Therapeutics Inc (NMRA) 最新ニュース
Head to Head Comparison: LadRx (OTCMKTS:CYTR) versus Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Franklin Resources Inc. Lowers Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by Barclays PLC - Defense World
Neumora Therapeutics Inc put volume heavy and directionally bearish - TipRanks
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by Geode Capital Management LLC - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Shares Up 7.2%Here's Why - MarketBeat
This Is What Whales Are Betting On Neumora Therapeutics - Benzinga
Neumora: KOASTAL-1 Readout For MDD Treatment Is First Study On Deck (NMRA) - Seeking Alpha
Neumora Therapeutics (NASDAQ:NMRA) Shares Down 3%Should You Sell? - MarketBeat
Neumora Therapeutics Target of Unusually High Options Trading (NASDAQ:NMRA) - Defense World
Neumora Therapeutics Sees Unusually High Options Volume (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by State Street Corp - MarketBeat
State Street Corp Has $23.66 Million Stock Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Commit To Buy Neumora Therapeutics At $5, Earn 105.2% Annualized Using Options - Nasdaq
(NMRA) Trading Report - Stock Traders Daily
What is HC Wainwright’s Estimate for NMRA Q1 Earnings? - Defense World
Q1 Earnings Forecast for NMRA Issued By HC Wainwright - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Given Buy Rating at HC Wainwright - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Earns Buy Rating from HC Wainwright - MarketBeat
Neumora Therapeutics' SWOT analysis: stock's potential in depression treatment market - Investing.com
Stock Traders Purchase High Volume of Neumora Therapeutics Call Options (NASDAQ:NMRA) - Defense World
Point72 Asset Management L.P. Takes Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
The Manufacturers Life Insurance Company Trims Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Holdings Raised by Charles Schwab Investment Management Inc. - MarketBeat
(NMRA) Proactive Strategies - Stock Traders Daily
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by Wexford Capital LP - MarketBeat
Intech Investment Management LLC Makes New $175,000 Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
RBC maintains $29 target on Neumora amid JNJ trial update By Investing.com - Investing.com UK
Fmr LLC Trims Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Cerity Partners LLC Purchases New Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Head-To-Head Analysis: Neumora Therapeutics (NMRA) vs. Its Competitors - Defense World
Neumora Therapeutics' SWOT analysis: stock poised for growth amid MDD trial - Investing.com Canada
Neumora Therapeutics’ (NMRA) Outperform Rating Reiterated at Royal Bank of Canada - Defense World
Neumora Therapeutics' (NMRA) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Contrasting Neumora Therapeutics (NMRA) and Its Competitors - Defense World
Head-To-Head Survey: Neumora Therapeutics (NMRA) vs. Its Rivals - Defense World
Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode - MSN
This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho - MSN
10 Best Small-Cap Stocks Ready To Explode - Insider Monkey
Financial Comparison: Neumora Therapeutics (NMRA) and Its Rivals - Defense World
HC Wainwright Issues Pessimistic Forecast for NMRA Earnings - Defense World
Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $21.67 - Defense World
Equities Analysts Set Expectations for NMRA FY2024 Earnings - Defense World
FY2024 Earnings Forecast for NMRA Issued By William Blair - MarketBeat
HC Wainwright Analysts Lower Earnings Estimates for NMRA - MarketBeat
Noteworthy Friday Option Activity: NMRA, WMT, CMRE - Nasdaq
This biotech’s stock may double on treatment for depression, says Mizuho - MarketWatch
SoftBank Group Corp.'s Strategic Reduction in Neumora Therapeuti - GuruFocus.com
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Neumora Therapeutics Inc (NMRA) 財務データ
収益
当期純利益
現金流量
EPS
1.76%
1.06%
大文字化:
|
ボリューム (24 時間):